艾多沙班抗栓治疗用于心房颤动合并稳定型冠心病
该多中心、开放标签、裁决者设盲随机试验在韩国18个中心纳入1040例心房颤动合并稳定型冠心病患者,比较艾多沙班单药与双联抗栓(艾多沙班加一种抗血小板药)。主要终点为12个月内全因死亡、心肌梗死、卒中、系统性栓塞、非计划紧急血运重建及大出血或临床相关非大出血的复合终点。结果显示,艾多沙班单药组主要终点事件34例(Kaplan-Meier估计6.8%),双联抗栓组79例(16.2%),HR 0.44(95%CI 0.30~0.65,P<0.001)。大出血或临床相关非大出血在单药组23例(4.7%),双联组70例(14.2%),HR 0.34(95%CI 0.22~0.53)。主要缺血事件累积发生率两组似乎相似。
要点
- 心房颤动合并稳定型冠心病患者,艾多沙班单药较双联抗栓降低12个月主要复合终点风险:34例(6.8%)vs 79例(16.2%),HR 0.44(95%CI 0.30~0.65,P<0.001)。
- 大出血或临床相关非大出血:艾多沙班单药组23例(4.7%)vs 双联抗栓组70例(14.2%),HR 0.34(95%CI 0.22~0.53)。
- 12个月主要缺血事件累积发生率在艾多沙班单药组与双联抗栓组似乎相似。
- 研究纳入韩国18个中心1040例患者,平均年龄72.1岁,女性22.9%,平均CHA2DS2-VASc评分4.3。
- 该研究为开放标签、裁决者设盲设计,稳定型冠心病定义为既往接受血运重建或药物治疗的冠心病。
适用人群与场景
- 心房颤动合并稳定型冠心病患者,稳定型冠心病定义为既往接受血运重建或药物治疗的冠心病。
- 研究在韩国18个中心进行,纳入1040例患者,平均年龄72.1岁,女性22.9%,平均CHA2DS2-VASc评分4.3。
诊断标准与关键阈值
- 卒中风险依据CHA2DS2-VASc评分评估,评分范围0~9分,评分越高卒中风险越大。
处置流程与药物剂量
- 艾多沙班单药方案:艾多沙班单药治疗,具体剂量原文未写明。
- 双联抗栓方案:艾多沙班联合一种抗血小板药,具体剂量原文未写明。
研究设计与关键结果
- 研究类型:多中心、开放标签、裁决者设盲随机试验,在韩国18个中心纳入1040例心房颤动合并稳定型冠心病患者。
- 分组:艾多沙班单药组524例,双联抗栓组(艾多沙班加一种抗血小板药)516例。
- 主要终点为12个月内全因死亡、心肌梗死、卒中、系统性栓塞、非计划紧急血运重建及大出血或临床相关非大出血的复合终点。
- 主要终点:艾多沙班单药组34例(Kaplan-Meier估计6.8%)vs 双联抗栓组79例(16.2%),HR 0.44(95%CI 0.30~0.65,P<0.001)。
- 12个月主要缺血事件累积发生率在两组似乎相似。
- 安全性终点大出血或临床相关非大出血:艾多沙班单药组23例(Kaplan-Meier估计4.7%)vs 双联抗栓组70例(14.2%),HR 0.34(95%CI 0.22~0.53)。
证据类型、等级与局限
- 证据类型:多中心、开放标签、裁决者设盲随机对照试验。
- 研究由CardioVascular Research Foundation等资助,临床试验注册号NCT03718559。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于心房颤动合并稳定型冠心病患者,艾多沙班单药较艾多沙班联合一种抗血小板药降低12个月主要复合终点风险(HR 0.44,95%CI 0.30~0.65)及大出血或临床相关非大出血风险(HR 0.34,95%CI 0.22~0.53),主要缺血事件累积发生率似乎相似。
- 原文未据此给出推荐。
指南或共识出处
- EPIC-CAD试验,临床试验注册号NCT03718559,发表于N Engl J Med。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Despite consistent recommendations from clinical guidelines, data from randomized trials on a long-term antithrombotic treatment strategy for patients with atrial fibrillation and stable coronary artery disease are still lacking.
METHODS: We conducted a multicenter, open-label, adjudicator-masked, randomized trial comparing edoxaban monotherapy with dual antithrombotic therapy (edoxaban plus a single antiplatelet agent) in patients with atrial fibrillation and stable coronary artery disease (defined as coronary artery disease previously treated with revascularization or managed medically). The risk of stroke was assessed on the basis of the CHA2DS2-VASc score (scores range from 0 to 9, with higher scores indicating a greater risk of stroke). The primary outcome was a composite of death from any cause, myocardial infarction, stroke, systemic embolism, unplanned urgent revascularization, and major bleeding or clinically relevant nonmajor bleeding at 12 months. Secondary outcomes included a composite of major ischemic events and the safety outcome of major bleeding or clinically relevant nonmajor bleeding.
RESULTS: We assigned 524 patients to the edoxaban monotherapy group and 516 patients to the dual antithrombotic therapy group at 18 sites in South Korea. The mean age of the patients was 72.1 years, 22.9% were women, and the mean CHA2DS2-VASc score was 4.3. At 12 months, a primary-outcome event had occurred in 34 patients (Kaplan-Meier estimate, 6.8%) assigned to edoxaban monotherapy and in 79 patients (16.2%) assigned to dual antithrombotic therapy (hazard ratio, 0.44; 95% confidence interval [CI], 0.30 to 0.65; P<0.001). The cumulative incidence of major ischemic events at 12 months appeared to be similar in the trial groups. Major bleeding or clinically relevant nonmajor bleeding occurred in 23 patients (Kaplan-Meier estimate, 4.7%) in the edoxaban monotherapy group and in 70 patients (14.2%) in the dual antithrombotic therapy group (hazard ratio, 0.34; 95% CI, 0.22 to 0.53).
CONCLUSIONS: In patients with atrial fibrillation and stable coronary artery disease, edoxaban monotherapy led to a lower risk of a composite of death from any cause, myocardial infarction, stroke, systemic embolism, unplanned urgent revascularization, or major bleeding or clinically relevant nonmajor bleeding at 12 months than dual antithrombotic therapy. (Funded by the CardioVascular Research Foundation and others; EPIC-CAD ClinicalTrials.gov number, NCT03718559.).
参考来源
- Cho MS, Kang DY, Ahn JM, et al. Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease. N Engl J Med. 2024. PMID: 39225258. doi:10.1056/NEJMoa2407362
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。